Senior insider sale
CHIEF SCIENTIFIC OFFICER at ENLIVEN THERAPEUTICS, INC. — senior position signals high conviction
$6.20M
237.50K shares
What this filing means
LYSSIKATOS JOSEPH P plans to sell 237.50K shares of ENLIVEN THERAPEUTICS, INC. valued at approximately $6.20M. Form 144 is a notice of intent to sell restricted or control securities — not a mandatory transaction. This filing provides advance warning of potential selling pressure.
Filed: 2/18/2026ACC: 0001974158-26-000020
Officer· CHIEF SCIENTIFIC OFFICER
Since Feb 2026
237.50K
Shares to sell
$6.20M
Approx. market value
75K
Acquired (3 months)
1
Planned
5 completed
Securities Acquired — Last 3 Months1
Founder shares
N/A
9/1/2019
75KTotal acquired75K
| Acquisition Date | Type | Amount Acquired | Gift |
|---|---|---|---|
9/1/2019 | Founder shares N/A | 75K | — |
| Total | 75K | ||
Planned & Completed Dispositions6
Completed
—Completed
Units to sell
5K
Market value
$145.2K
2/6/2026
—Completed
Units to sell
20K
Market value
$535.1K
1/20/2026
—Completed
Units to sell
91.20K
Market value
$2.48M
1/9/2026
—Completed
Units to sell
41.30K
Market value
$993.4K
1/8/2026
—Completed
Units to sell
5K
Market value
$84.2K
12/19/2025
Planned — Approximate Date
NasdaqPlanned
Units to sell
75K
Market value
$1.96M
2/18/2026
Total
Units
237.50K
Value
$6.20M
| Date | Units to Sell | Approx. Market Value | Exchange | Status |
|---|---|---|---|---|
| Completed | ||||
2/6/2026 | 5K | $145.2K | — | Completed |
1/20/2026 | 20K | $535.1K | — | Completed |
1/9/2026 | 91.20K | $2.48M | — | Completed |
1/8/2026 | 41.30K | $993.4K | — | Completed |
12/19/2025 | 5K | $84.2K | — | Completed |
| Planned — Approximate Date | ||||
2/18/2026 | 75K | $1.96M | Nasdaq | Planned |
| Total | 237.50K | $6.20M | ||